TOLREMO therapeutics AG

 

About TOLREMO therapeutics AG

A majority of all cancer therapies fail because of the development of drug resistance. Over time, tumors acquire complex resistance-causing mutations, that make second- and third-line therapies very inefficient. We identified novel mechanisms that predispose cancer cells to the development of drug resistance before it is genetically and irreversibly manifested. Based on this knowledge, we develop add-on therapies that can be combined with cancer drugs right at the beginning of a therapy to boost its longterm efficacy. Our unique drug resistance platform combines real-world medicine-guided, cutting-edge science with proprietary drug screening modalities and a preclinical validation pipeline. The created medicines are designed to be used alongside diagnostic solutions to ensure that the right patient is treated with the right drug at the right time. Within the short time since foundation (March 2017), we have leveraged our profound understanding of a novel scientific drug resistance framework to develop new chemical matter in two parallel drug discovery and development programs.

Therapeutic Areas

Oncology

Technologies

Small molecules

Company Type

Biotechnology – Therapeutics

State of Ownership

Private

Sponsorship Group

Networker

Topics

Editions participated in:

March 2019